A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan; Almirall, S.A.
• Collaborator: Allergan
• Treatments: Dapsone

Criteria

Inclusion Criteria:

• Diagnosis of acne vulgaris

• Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight, tanning beds) throughout the study

Exclusion Criteria:

• Severe cystic acne, acne conglobata, acne fulminans, or secondary acne

• Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling, comedo extraction) in the past week

• Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]), retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks

• Use of birth control pills strictly for acne control